Prostate Cancer Reports


Volume 2 Number 4
 April 2014

Home > Prostate Cancer Reports > Volume 2 - Year 2014, Number 4, April 2014

CONTENTS

Diagnosis and evaluation
Etiology and pathogenesis
Integrative medicine
Nomograms
Prognosis and outcome
Recurrence
Screening and early detection
Staging
Treatment



DIAGNOSIS AND EVALUATION

Gorin MA, Chalfin HJ, Epstein JI, Feng Z, Partin AW, Trock BJ.
Predicting the risk of non-organ-confined prostate cancer when perineural invasion is found on biopsy.
Urology. 2014 May;83(5):1117-21. doi: 10.1016/j.urology.2013.12.042. Epub 2014 Mar 19.
Abstract | Related citations

ETIOLOGY AND PATHOGENESIS


Peck B, Schulze A.
Cholesteryl esters: fueling the fury of prostate cancer.
Cell Metab. 2014 Mar 4;19(3):350-2. doi: 10.1016/j.cmet.2014.02.012.
Abstract | Related citations


Twu O, Dessí D, Vu A, Mercer F, Stevens GC, de Miguel N, Rappelli P, Cocco AR, Clubb RT, Fiori PL, Johnson PJ.
Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responses.
Proc Natl Acad Sci U S A. 2014 May 19. pii: 201321884. [Epub ahead of print]
Abstract | Related citations


Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, Cheng L, Masterson TA, Liu X, Ratliff TL, Cheng JX.
Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness.
Cell Metab. 2014 Mar 4;19(3):393-406. doi: 10.1016/j.cmet.2014.01.019.
Abstract | Full text | Related citations

INTEGRATIVE MEDICINE


Ajibade AA, Kirk JS, Karasik E, Gillard B, Moser MT, Johnson CS, Trump DL, Foster BA.
Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer.
PLoS One. 2014 Feb 26;9(2):e89555. doi: 10.1371/journal.pone.0089555. eCollection 2014.
Abstract | Full text | Related citations


Lu Y, Zhai L, Zeng J, Peng Q, Wang J, Deng Y, Xie L, Mo C, Yang S, Li S, Qin X.
Coffee consumption and prostate cancer risk: an updated meta-analysis.
Cancer Causes Control. 2014 May;25(5):591-604. doi: 10.1007/s10552-014-0364-8. Epub 2014 Mar 2.
Abstract | Related citations


Schwingshackl L, Hoffmann G.
Adherence to Mediterranean diet and risk of cancer: A systematic review and meta-analysis of observational studies.
Int J Cancer. 2014 Mar 6. doi: 10.1002/ijc.28824. [Epub ahead of print]
Abstract | Related citations

NOMOGRAMS

Ahn JH, Lee JZ, Chung MK, Ha HK
Nomogram for prediction of prostate cancer with serum prostate specific antigen less than 10 ng/mL.
J Korean Med Sci. 2014 Mar;29(3):338-42. doi: 10.3346/jkms.2014.29.3.338. Epub 2014 Feb 27.
Abstract | Full text | Related citations

PROGNOSIS AND OUTCOME


Oncologic outcomes

Abern MR, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ.
The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer.
Cancer. 2014 Jun 1;120(11):1656-62. doi: 10.1002/cncr.28647. Epub 2014 Mar 19.
Abstract | Related citations


PCa-specific mortality

Cheney MD, Chen MH, Zhang D, Phillips JG, Loffredo MJ, D'Amico AV.
Greatest Percentage of Involved Core Length and the Risk of Death From Prostate Cancer in Men With Highest Gleason Score ≥ 7.
Clin Genitourin Cancer. 2014 Feb 4. pii: S1558-7673(14)00014-7. doi: 10.1016/j.clgc.2014.01.006. [Epub ahead of print]
Abstract | Related citations


Keane FK, Chen MH, Zhang D, Loffredo MJ, Kantoff PW, Renshaw AA, D'Amico AV.
The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease.
Cancer. 2014 Mar 6. doi: 10.1002/cncr.28609. [Epub ahead of print]
Abstract | Related citations

RECURRENCE

Inoue H, Nishimura K, Yamaguchi S, Nonomura N, Hara T.
Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.
Int J Clin Oncol. 2014 Mar 21. [Epub ahead of print]
Abstract | Related citations


Lohm G, Lütcke J, Jamil B, Höcht S, Neumann K, Hinkelbein W, Wiegel T, Bottke D.
Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy : Long-term follow-up of a single-center survey.
Strahlenther Onkol. 2014 Feb 28. [Epub ahead of print]
Abstract | Related citations


Sanpaolo P, Barbieri V, Genovesi D.
Biologically effective dose and definitive radiation treatment for localized prostate cancer : Treatment gaps do affect the risk of biochemical failure.
Strahlenther Onkol. 2014 Mar 4. [Epub ahead of print]
Abstract | Related citations


Zanatta DA, Andrade RJ, Pacagnan EF, Munchen LW, Assumpção RA, Mercante VC, Simonetti GM.
Early stage prostate cancer: biochemical recurrence after treatment.
Int Braz J Urol. 2014 Mar-Apr;40(2):137-45. doi: 10.1590/S1677-5538.IBJU.2014.02.02.
Abstract | Full text | Related citations


Risk stratification

Jung JW, Lee JK, Hong SK, Byun SS, Lee SE.
Stratification of Patients with Intermediate-risk Prostate Cancer.
BJU Int. 2014 Feb 25. doi: 10.1111/bju.12703. [Epub ahead of print]
Abstract | Related citations

SCREENING AND EARLY DETECTION


Prostate-specific antigen

Durmaz T, Ayhan H, Keleş T, Bilen E, Akçay M, Akar Bayram N, Bozkurt E.
Is there a relationship between acute coronary syndrome and prostate specific antigen level?
Urol J. 2014 Mar 4;11(1):1278-86.
Abstract | Full text | Related citations


Safarinejad MR.
Is there a relationship between acute coronary syndrome and prostate specific antigen level?
Urol J. 2014 Mar 4;11(1):1287-8.
Abstract | Full text | Related citations


Vickers AJ, Thompson IM, Klein E, Carroll PR, Scardino PT.
A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer.
Urology. 2014 Mar;83(3):592-6. doi: 10.1016/j.urology.2013.09.075.
Abstract | Related citations

STAGING

Gleason score

Giunchi F, Brunocilla E, Borghesi M, Rizzi S, Ricci MS, Romagnoli D, Martorana G, Schiavina R, Fiorentino M.
Revised Gleason Grading System Is a Better Predictor of Indolent Prostate Cancer at the Time of Diagnosis: Retrospective Clinical-Pathological Study on Matched Biopsy and Radical Prostatectomy Specimens.
Clin Genitourin Cancer. 2014 Feb 4. pii: S1558-7673(14)00017-2. doi: 10.1016/j.clgc.2014.01.009. [Epub ahead of print]
Abstract | Related citations

TREATMENT

Special topics

Statins

Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ.
Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
BJU Int. 2014 Mar 3. doi: 10.1111/bju.12720. [Epub ahead of print]
Abstract | Related citations


Kim JH, Cox ME, Wasan KM.
Effect of simvastatin on castration-resistant prostate cancer cells.
Lipids Health Dis. 2014 Mar 26;13:56. doi: 10.1186/1476-511X-13-56.
Abstract | Full text | Related citations


First-line treatment

Umbehr MH, Largo RA, Gfeller S, Tremp M, Poyet C, Paul M, Sulser T, Müntener M.
Bilaterally Positive Biopsy Cores Are Associated with Non-Organ-Confined Disease in Prostate Cancer Patients Eligible for Active Surveillance.
Urol Int. 2014 Mar 15. [Epub ahead of print]
Abstract | Related citations


Localized PCa

Potosky AL, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Jiang M, Tsai HT, Luta G, Keating NL, Smith MR, Van Den Eeden SK.
Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.
J Clin Oncol. 2014 May 1;32(13):1324-30. doi: 10.1200/JCO.2013.52.5782. Epub 2014 Mar 17.
Abstract | Related citations


Second-line-treatment

Advanced PCa

Hong JH, Kim IY.
Nonmetastatic castration-resistant prostate cancer.
Korean J Urol. 2014 Mar;55(3):153-60. doi: 10.4111/kju.2014.55.3.153. Epub 2014 Mar 13.
Abstract | Full text | Related citations


Sartor O, Gillessen S.
Treatment sequencing in metastatic castrate-resistant prostate cancer.
Asian J Androl. 2014 May-Jun;16(3):426-31. doi: 10.4103/1008-682X.126378.
Abstract | Full text | Related citations


Treatment comparison

D'Amico AV.
Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: less cost at the expense of more genitourinary toxicity is a concerning but testable hypothesis.
J Clin Oncol. 2014 Apr 20;32(12):1183-5. doi: 10.1200/JCO.2014.55.2380. Epub 2014 Mar 10.
Abstract | Full text | Related citations


Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP.
Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.
J Clin Oncol. 2014 Apr 20;32(12):1195-201. doi: 10.1200/JCO.2013.53.8652. Epub 2014 Mar 10.
Abstract | Related citations


Treatment complications

Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X.
An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.
PLoS One. 2014 Mar 5;9(3):e89960. doi: 10.1371/journal.pone.0089960. eCollection 2014.
Abstract | Full text | Related citations


Mukherjee S, Reddy CA, Ciezki JP, Abdel-Wahab M, Tiu RV, Copelan E, Advani AA, Saunthararajah Y, Paulic K, Hobson S, Maciejewski JP, Bolwell BJ, Kalaycio M, Dreicer R, Klein EA, Sekeres MA.
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation.
J Natl Cancer Inst. 2014 Mar;106(3):djt462. doi: 10.1093/jnci/djt462. Epub 2014 Feb 27.
Abstract | Related citations